AGEN
AgenusDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The best post-print bull read is that Q1 moved BOT+BAL from setup toward execution: early-access revenue reached $4.6 million, BATTMAN enrollment started in April, and the Zydus deal added capital plus manufacturing support, while the SEC investigation ended with no enforcement recommendation [#8-K-2026-05-11] [#10-Q-2026-05-11].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +81.1.
What can break
Clinical and regulatory execution risk remains high because the thesis still depends on BATTMAN enrollment, data-package completion, and planned U.S./E.U. submission pathways [#8-K-2026-05-11] [#10-Q-2026-05-11].
Momentum
86
Value
41
Sentiment
13
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.00 · Bull $6.00 · Bear $1.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $19.00
Why
Momentum86 · Δ7d +81.1
Value41 · Δ7d -0.1
Sentiment13 · Δ7d -35.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
86
26% active weight
Current posture
7d trendImproving
Δ7d
+81.1
Δ21d
+84.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
13
34% active weight
Current posture
7d trendSoftening
Δ7d
-35.0
Δ21d
-43.7
Why this grade
Composite grade D. Momentum 86.2 / Value 41.1 / Sentiment 12.6
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$208.63M
Beta
1.62
Shares Out
41.64M
P/E (TTM) · Derived
-1473.5
P/S (TTM)
1.03
P/FCF (TTM) · Derived
-1.94
Rev YoY
+40.2%
EPS YoY
-198.9%
Gross Margin
+93.3%
Op Margin
+37.9%
Net Debt
$331.9M
Current Ratio
0.38
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology